CLINUVEL PHARMACEUTICALS/ AU000000CUV3 /
2024-03-19 12:54:32 PM | Chg. -0.1360 | Volume | Bid12:54:32 PM | Ask12:54:32 PM | High | Low |
---|---|---|---|---|---|---|
8.4360EUR | -1.59% | 2,099 Turnover: 17,628.4780 |
8.3240Bid Size: 853 | 8.4380Ask Size: 4,700 | 8.4360 | 8.3500 |
GlobeNewswire
2018-12-19
Phase II study: SCENESSE® in combination with narrowband ultraviolet B (NB-UVB) achieves repigmentat...
GlobeNewswire
2018-06-25
FDA to Review Australian Drug for Genetic Disorder of Absolute Light Intolerance
GlobeNewswire
2017-04-12
CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board
GlobeNewswire
2016-06-01
Nasdaq Welcomes Additional Companies to the Nasdaq International Designation